Samsung Biologics is expanding across capacity, geography, and modality. The company completed a $353 million acquisition of a former GSK site in Rockville, MD, adding 60,000 L of cGMP capacity and bringing its global total to 845,000 L. In Songdo, South Korea, it's building an open innovation hub with Lilly Gateway Labs for up to 30 biotech firms, opening July 2027. Land for BioCampus III has been secured for next-generation modalities. And the CDMO also announced a CHF 1.46 billion agreement to acquire PolyPeptide Group, entering the peptide therapeutics space.
Read the full article in GEN for broader industry context.
Samsung Biologics is expanding across capacity, geography, and modality. The company completed a $353 million acquisition of a former GSK site in Rockville, MD, adding 60,000 L of cGMP capacity and bringing its global total to 845,000 L. In Songdo, South Korea, it's building an open innovation hub with Lilly Gateway Labs for up to 30 biotech firms, opening July 2027. Land for BioCampus III has been secured for next-generation modalities. And the CDMO also announced a CHF 1.46 billion agreement to acquire PolyPeptide Group, entering the peptide therapeutics space.
Read the full article in GEN for broader industry context.
Share article
Related Content